Screener
ADMA Biologics ADMA Stock-Based Comp
Stock-Based Comp at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001140361-26-031445
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Gain on sale of plasma centers | (7,980) | - |
| Loss on disposal of fixed assets | 42 | - |
| Deferred income tax provision | 3,295 | 5,045 |
| Stock-based compensation | 12,464 | 9,587 |
| Amortization of debt discount | 383 | 350 |
| Loss on extinguishment of debt | - | 1,159 |
| Amortization of license revenue | (71) | (71) |
| Changes in operating assets and liabilities: |
Item 1. Financial Statements.
FAQ
- What is ADMA Biologics's stock-based comp?
- ADMA Biologics (ADMA) reported stock-based comp of $75K in Q2 2026.
- How has ADMA Biologics's stock-based comp changed year-over-year?
- ADMA Biologics's stock-based comp increased by 47.1% year-over-year, from $51K to $75K.
- What is the long-term trend for ADMA Biologics's stock-based comp?
- Over 4 years (2021 to 2025), ADMA Biologics's stock-based comp has grown at a 44.3% compound annual growth rate (CAGR), from $3.49M to $15.11M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about ADMA Biologics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude